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Introduction
Mucopolysaccaridosis (MPS) Type I, also called MPSI, is a lysosomal storage disorder caused by mutations in the gene encoding the lysosomal enzyme, α-L-iduronidase (IDUA).
MPSI patients are treated with enzyme replacement therapy (Brady and Schiffmann, 2004) , and weekly intravenous infusions of the recombinant IDUA enzyme. However, many patients with MPSI have Hurler's syndrome, where the disorder also affects the central nervous system (CNS).
Enzyme replacement therapy is not effective for the CNS (Wraith, 2001) , because the IDUA, a large molecule drug, does not cross the blood-brain barrier (BBB) and does not penetrate the brain from blood (Miebach, 2005) .
Recombinant enzyme such as IDUA can be re-engineered as BBB-penetrating pharmaceuticals by fusion of the IDUA to a genetically engineered monoclonal antibody (MAb) against the human insulin receptor (HIR) (Boado et al, 2008) . The insulin receptor is expressed at the human BBB (Pardridge et al, 1985) . The HIRMAb binds the BBB insulin receptor, and acts as a molecular Trojan horse to ferry the fused IDUA enzyme across the BBB. The insulin receptor is also expressed on brain cells, and the HIRMAb also mediates endocytosis into target cells, where the fusion protein is then triaged to the lysosomal compartment of the cell (Boado et al, 2008) .
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70% relative humidity) on a 12-h light/dark cycle. Lab Diet Certified Primate Diet (PMI Nutrition International) was provided twice daily. Animals were fasting prior to all study drug infusions, as food was withheld the morning prior to drug infusion. Tap water was provided ab libitum. All aspects of the primate study performed at MPI Research was conducted in strict compliance with the United States Food and Drug Administration Good Laboratory Practice (GLP) Regulations, 21 CFR Part 58. All procedures were in compliance with the Animal Welfare Act Regulations, and were approved by the Institutional Animal Care and Use Committee.
The primates were treated with 0 mg/kg (6 males, 6 females), 3 mg/kg (4 males, 4 females), 9 mg/kg (4 males, 4 females), or 30 mg/kg (6 males, 6 females) of the HIRMAb-IDUA fusion protein administered as an intravenous infusion over a 30-min period in 50 mL of either normal saline or 10% dextrose in normal saline. In the 26-week toxicity study, the doses were administered every 7 days for 26 consecutive weeks. The HIRMAb-IDUA fusion protein was administered on a weekly basis, because this parallels the current standard practice in the treatment of Hurler's syndrome, which utilizes weekly IV infusions of the recombinant IDUA (Wraith, 2001; Miebach, 2005) . For study drug infusion at week 1 and week 25, blood was removed from the femoral vein and collected in tubes with 2, 5, 30, 35, 90 min, 3, 6 , 23 hrs after the start of the 30 min IV infusion of the HIRMAb-IDUA fusion protein. The blood was separated into plasma which was then stored at -70C until analysis. Fasting plasma glucose was measured monthly during the study. During the first week, CSF was removed via the cisterna magna at 0, 3, and 23 hrs after the IV infusion of the HIRMAb-IDUA fusion protein.
Fasting plasma glucose was measured on blood removed at weeks 0, 4, 8, 13, 16, 20, and 24. This article has not been copyedited and formatted. The final version may differ from this version. 
Results
The HIRMAb-IDUA fusion protein was infused IV over 30 min in 50 mL normal saline in Rhesus monkeys at 4 doses (0, 3, 9, 30 mg/kg). Plasma glucose was measured at 0, 2, 5, 30, 35, 90, 180, 360 , and 1380 min after the start of the 30 min infusion, and the values are reported in Table 1 either by sex or combined sexes. There are no significant differences between sexes at any time point (Table 1 ). The glucose in the fusion protein treated animals (combined sexes) was 20-29% lower than the saline controls at 30 and 35 minutes after start of the 30 min drug infusion at all 3 doses of fusion protein with no dose relationships ( Table 1 ). The plasma glucose is decreased 31% and 47% at 90 and 180 minutes only in the high dose group, 30 mg/kg (Table   1 ). Figure There were no differences in the T 1/2 among all treatment groups, and glucose was cleared from plasma with a T 1/2 of 32-35 minutes (Table 2) .
Plasma glucose was measured monthly in all monkeys prior to the IV infusion of the study drug, and the plasma glucose values are shown in Table 3 by sex and for combined groups.
There are no sex differences and no upward or downward trend in plasma glucose over the course of 24 weeks.
Glucose was measured in CSF at 0, 3, and 23 hours after the 30 min infusion of HIRMAb-IDUA fusion protein at each of the 4 doses (0, 3, 9, and 30 mg/kg) in normal saline.
The only significant difference in CSF glucose was a 48% decrease at 3 hours in the 30 mg/kg treatment group (Figure 3) . The CSF glucose, at 3 hours after drug infusion, in all 40 monkeys in the study correlated with the plasma glucose, at 3 hours after drug infusion, and the average CSF/plasma glucose ratio was 54% for all monkeys (Figure 4 ). There were no significant differences in the glucose concentration in CSF at 0 and 23 hours in any of the 4 treatment groups. The CSF glucose at 0 hours was 63 ± 16, 69 ± 20, 58 ± 6, and 62 ± 12 mg%, and at 23 hours was 54 ± 9, 67 ± 18, 52 ± 8, and 63 ± 16 mg%, respectively after administration of 0, 3, 9, and 23 mg/kg HIRMAb-IDUA fusion protein (mean ± S.D.).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The results of the studies are consistent with the following conclusions. First, high doses, 30 mg/kg, of the HIRMAb-IDUA fusion protein in fasting Rhesus monkeys cause hypoglycemia with a nadir of 39 ± 5 mg% at 180 min after a 30 min infusion of the fusion protein in 50 mL of normal saline (Table 1) . Second, the hypoglycemia can be severe in some monkeys as the nadir was as low as 11 mg% in 2 monkeys at the 30 mg/kg dose of fusion protein (Figure 1) . Third, the hypoglycemia is eliminated by the inclusion of glucose in the infusion solution (Figure 2) . Fourth, the rate of clearance of glucose from plasma, which is a measure of glucose tolerance, is unchanged in all treatment groups at the end of the 26 weeks of fusion protein dosing (Figure 2) , and the half-time of glucose clearance at all doses in the same, 32-35 minutes (Table 2) . Fifth, there is no evidence of impaired glucose tolerance with chronic fusion protein treatment, as the monthly fasting plasma glucose is unchanged in all treatment groups over the course of the 6 months of treatment (Table 3) . Sixth, the CSF glucose is decreased at 3 hours after IV infusion of the 30 mg/kg of the HIRMAb-IDUA fusion protein in normal saline, and the CSF glucose parallels the corresponding plasma glucose in each monkey (Figure 4) .
A monoclonal antibody against the alpha-subunit of the human insulin receptor may have either agonist or antagonist properties. Antibodies against the insulin receptor that demonstrate agonist properties cause an increase in glucose uptake by cells (Brunetti et al, 1989) , which is associated with an increase in glucose clearance from plasma (Bhaskar et al, 2012) . The HIRMAb domain of the HIRMAb-IDUA fusion protein shows agonist properties, albeit only at the highest treatment dose of 30 mg/kg. At this dose, hypoglycemia is induced, which peaks at 3 hours after a 30 min infusion of the HIRMAb-IDUA fusion protein in normal saline (Table 1, Figure 1 ). The hypoglycemia is eliminated when glucose is added to the fusion protein infusion Figure 2 ). An insulin receptor antibody with antagonist action can cause hyperglycemia and impaired glucose tolerance (Malek et al, 2010) . The HIRMAb domain of the HIRMAb-IDUA fusion protein exhibits no antagonist properties, as fasting hyperglycemia is not induced (Table 3) , and the rate constant of glucose clearance from plasma is unchanged (Table 2) The concentration of glucose in CSF is also reduced at 3 hours after the IV infusion of the HIRMAb-IDUA fusion protein at a dose of 30 mg/kg in normal saline (Figure 3 ). Insulin does not affect glucose uptake by brain (Hasselbalch et al, 1999) , and the CSF glucose is regulated by the plasma glucose concentration. The direct relationship between CSF and plasma glucose is demonstrated in this study (Figure 4) , and the mean CSF/plasma glucose ratio is 0.54 (Figure 4 ). This value is in agreement with the CSF/plasma ratio reported in either humans or Rhesus monkeys, which is 0.5-0.6 (Powers, 1981; Davis et al, 1993) . Therefore, high doses of the HIRMAb-IDUA fusion protein have no direct effect on glucose distribution in CSF, and CSF glucose concentrations parallel the corresponding concentration of glucose in plasma. the HIRMAb-IDUA fusion protein is 0.6-1 mg/kg (Boado et al, 2008 (Boado et al, , 2011 , no alterations in plasma or CSF glucose are expected in humans.
The effect of high doses of the HIRMAb-IDUA fusion protein on plasma glucose is transient as the plasma glucose increases between 180 and 360 minutes after infusion (Figure 1) .
The rapid reversal of the plasma glucose is consistent with the rapid removal of the HIRMAb-IDUA fusion protein from plasma, owing to uptake by peripheral tissues. At a dose of 20 mg/kg in Rhesus monkeys, the HIRMAb-IDUA fusion protein is rapidly cleared from plasma with a systemic clearance of 3.3 ± 0.4 mL/min/kg and a high systemic volume of distribution, 393 ± 75 mL/kg ). The mean residence time of the fusion protein in the circulation in Rhesus monkeys is 121 ± 24 minutes ). Therefore, the return to normoglycemia by 6 hours after drug infusion (Table 1) is consistent with nearly complete removal of the fusion protein from the circulation.
Lower doses of HIRMAb-IDUA fusion protein do not cause hypoglycemia. In a previous study with a 20 mg/kg dose of the HIRMAb-IDUA fusion protein in Rhesus monkeys, no reduction in plasma or CSF glucose was observed ). In another study, a HIRMAb fusion protein was administered to Rhesus monkeys by bolus intravenous injection at 10 mg/kg every 12 hours for 5 consecutive doses, and no hypoglycemia was observed ). In the present study, there are only modest reductions in glucose at 0-5 minutes after termination of the 30 minute infusion, and no significant reductions in plasma glucose at 90-1380 min after the start of the 30 minute IV infusion of 3 or 9 mg/kg doses of the HIRMAb-IDUA fusion protein in normal saline (Table 1) treatment with the mouse homologue of the HIRMAb-IDUA fusion protein, and the treatment dose is 1 mg/kg of fusion protein intravenously (Boado et al, 2011) . The level of IgG-enzyme penetration of the brain following IV administration is comparable in mice and Rhesus monkeys, where the brain uptake in either species is about 1% of injected dose (ID)/brain (Boado et al, 2008; Zhou et al, 2012) . Based on the brain uptake in the primate of 1% ID/brain, and the endogenous IDUA enzyme activity in the human brain, a treatment dose of 0.6 mg/kg is predicted to replace >50% of the IDUA enzyme activity in the brain (Boado et al, 2008 ).
In conclusion, these studies show that the HIRMAb domain of the HIRMAb-IDUA fusion protein has weak insulin agonist properties that are observed only at the highest dose of 30 mg/kg, which may be has much as 30-fold above planned therapeutic doses of the fusion protein.
Hypoglycemia is not observed following the administration of doses lower than 30 mg/kg. These observations are corroborated by a prior study, which showed no hypoglycemia following the IV infusion of the HIRMAb-IDUA fusion protein in saline at doses up to 20 mg/kg in Rhesus monkeys . Any concern about hypoglycemia is mitigated by simply adding dextrose to the saline infusion of drug. The present study shows that a 10% dextrose additive is not necessary, as this dose of glucose causes transient hyperglycemia (Figure 2) . A preferred formulation is normal saline with 5% dextrose for routine administration of HIRMAb-derived fusion proteins. Parameters determined by non-linear regression analysis of the plasma glucose between 30 and 90 minutes after a 30 min infusion of 10% glucose. Data are means ± SE for combined sexes. T1/2=half-time of glucose clearance from blood after termination of the glucose infusion.
